VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical…
FMX114 demonstrated preliminary clinical safety and pharmacokinetics in Phase 1b study VYN201 shows promising preclinical…
Two pre-clinical trials based on MEAI exhibited a significant suppressive effect on alcohol consumption in…
PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) — Oyster Point Pharma, Inc. (Nasdaq: OYST), a…
SOUTH SAN FRANCISCO, Calif., March 17, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…
BOSTON, March 17, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical…
TORONTO, March 17, 2022 (GLOBE NEWSWIRE) — Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB:…
IND submission for lead program CNTY-101 on track for mid 2022; Phase 1 ELiPSE-1 trial…
GAITHERSBURG, Md., March 17, 2022 (GLOBE NEWSWIRE) — NexImmune, Inc. (Nasdaq: NEXI) and Zephyr AI (Zephyr)…
JENA, Germany, March 17, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical…
VANCOUVER, British Columbia, March 17, 2022 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the…
CALGARY, Alberta, March 17, 2022 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix”) (TSX:RVX) today announced the…
CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022…
LEAMINGTON, Ontario, March 17, 2022 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”)…
WINNIPEG, Manitoba, March 17, 2022 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the…
TORONTO, Ontario and CAMBRIDGE, Massachusetts , March 17, 2022 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc….
NEW YORK and VIENNA, Austria, March 17, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ:…
Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for…
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage…
Over $140M in capital raised in initial public offering in 2021; Cash runway through first…
Harmony remains ongoing, with OLE study intended to gain insights into long-term exposure to ADP101…